新型主动脉瓣狭窄多基因风险评分与临床风险因素的风险估计比较
PRS与主动脉瓣狭窄显著相关,在MVP测试样本中每1 SD的OR为1.41,在TIMI试验中每1 SD的HR为1.44。除年龄外,PRS的表现与大多数临床风险因素相当,且在给定年龄范围内遗传与临床风险因素叠加,提供3-4倍的风险梯度;但将PRS加入仅含临床风险因素的模型仅使风险区分度提高0.01-0.02。
要点
- 除年龄外,PRS对主动脉瓣狭窄的风险估计与多数临床风险因素相当
- 遗传与临床风险因素叠加可提供3-4倍风险梯度,但PRS仅小幅改善整体风险区分度
核心结论
- 主动脉瓣狭窄PRS与临床风险因素独立相关,除年龄外表现与多数风险因素相当,但仅小幅改善整体风险区分度。
研究设计与样本
- 纵向队列研究,使用Million Veteran Program(2011-2020)、UK Biobank(2006-2010)和6项TIMI试验的数据。
- MVP中位年龄67岁,92%为男性;TIMI试验中位年龄66岁,71%为男性。
主要发现
- 在TIMI试验中每1 SD的HR为1.44(95%CI 1.27-1.62,P=3.2×10^-9)。
- 除年龄外,PRS表现与大多数风险因素相当,遗传与临床风险因素叠加提供3-4倍风险梯度。
- 加入PRS后C指数在MVP中从0.78升至0.79,在TIMI中从0.71升至0.73。
临床怎么用
- 主动脉瓣狭窄PRS可作为遗传风险标志物,与临床风险因素联合用于风险分层,但增量价值有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Polygenic risk scores (PRSs) have proven to be as strong as or stronger than established clinical risk factors for many cardiovascular phenotypes. Whether this is true for aortic stenosis remains unknown. OBJECTIVE: To develop a novel aortic stenosis PRS and compare its aortic stenosis risk estimation to established clinical risk factors. DESIGN, SETTING, AND PARTICIPANTS: This was a longitudinal cohort study using data from the Million Veteran Program (MVP; 2011-2020), UK Biobank (2006-2010), and 6 Thrombolysis in Myocardial Infarction (TIMI) trials, including DECLARE-TIMI 58 (2013-2018), FOURIER (TIMI 59; 2013-2017), PEGASUS-TIMI 54 (2010-2014), SAVOR-TIMI 53 (2010-2013), SOLID-TIMI 52 (2009-2014), and ENGAGE AF-TIMI 48 (2008-2013), which were a mix of population-based and randomized clinical trials. Individuals from UK Biobank and the MVP meeting a previously validated case/control definition for aortic stenosis were included. All individuals from TIMI trials were included unless they had a documented preexisting aortic valve replacement. Analysis took place from January 2022 to December 2023. EXPOSURES: PRS for aortic stenosis (developed using data from MVP and validated in UK Biobank) and other previously validated cardiovascular PRSs, defined either as a continuous variable or as low (bottom 20%), intermediate, and high (top 20%), and clinical risk factors. MAIN OUTCOMES: Aortic stenosis (defined using International Classification of Diseases or Current Procedural Terminology codes in UK Biobank and MVP or safety event data in the TIMI trials). RESULTS: The median (IQR) age in MVP was 67 (57-73) years, and 135 140 of 147 104 participants (92%) were male. The median (IQR) age in the TIMI trials was 66 (54-78) years, and 45 524 of 59 866 participants (71%) were male. The best aortic stenosis PRS incorporated 5 170 041 single-nucleotide variants and was associated with aortic stenosis in both the MVP testing sample (odds ratio, 1.41; 95% CI, 1.37-1.45 per 1 SD PRS; P = 4.6 × 10-116) and TIMI trials (hazard ratio, 1.44; 95% CI, 1.27-1.62 per 1 SD PRS; P = 3.2 × 10-9). Among genetic and clinical risk factors, the aortic stenosis PRS performed comparably to most risk factors besides age, and within a given age range, the combination of clinical and genetic risk factors was additive, providing a 3- to 4-fold increased gradient of risk of aortic stenosis. However, the addition of the aortic stenosis PRS to a model including clinical risk factors only improved risk discrimination of aortic stenosis by 0.01 to 0.02 (C index in MVP: 0.78 with clinical risk factors, 0.79 with risk factors and aortic stenosis PRS; C index in TIMI: 0.71 with clinical risk factors, 0.73 with risk factors and aortic stenosis PRS). CONCLUSIONS: This study developed and validated 1 of the first aortic stenosis PRSs. While aortic stenosis genetic risk was independent from clinical risk factors and performed comparably to all other risk factors besides age, genetic risk resulted in only a small improvement in overall aortic stenosis risk discrimination beyond age and clinical risk factors. This work sets the stage for further development of an aortic stenosis PRS.
引用
- Small AM, Melloni GEM, Kamanu FK, et al. Novel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic Stenosis. JAMA Cardiol. 2024. PMID: 38416462. doi:10.1001/jamacardio.2024.0011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。